Vaxcyte, Inc.

NasdaqGS:PCVX Stock Report

Market Cap: US$10.8b

Vaxcyte Management

Management criteria checks 4/4

Vaxcyte's CEO is Grant Pickering, appointed in Nov 2013, has a tenure of 11.08 years. total yearly compensation is $12.14M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $55.73M. The average tenure of the management team and the board of directors is 4.6 years and 5.6 years respectively.

Key information

Grant Pickering

Chief executive officer

US$12.1m

Total compensation

CEO salary percentage5.3%
CEO tenure11.1yrs
CEO ownership0.5%
Management average tenure4.6yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Dec 08
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 06

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Aug 24
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

May 10
Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Dec 27
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Vaxcyte appoints new CBO, CMO

Oct 11

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

CEO Compensation Analysis

How has Grant Pickering's remuneration changed compared to Vaxcyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$508m

Jun 30 2024n/an/a

-US$497m

Mar 31 2024n/an/a

-US$437m

Dec 31 2023US$12mUS$640k

-US$402m

Sep 30 2023n/an/a

-US$300m

Jun 30 2023n/an/a

-US$265m

Mar 31 2023n/an/a

-US$245m

Dec 31 2022US$14mUS$601k

-US$223m

Sep 30 2022n/an/a

-US$174m

Jun 30 2022n/an/a

-US$143m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$5mUS$575k

-US$100m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$83m

Dec 31 2020US$3mUS$481k

-US$89m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$596kUS$426k

-US$50m

Compensation vs Market: Grant's total compensation ($USD12.14M) is about average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: Grant's compensation has been consistent with company performance over the past year.

CEO

Grant Pickering (56 yo)

11.1yrs

Tenure

US$12,135,683

Compensation

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Leadership Team

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder11.1yrsUS$12.14m0.52%
$ 55.7m
Andrew Guggenhime
President & CFO4.6yrsUS$5.42m0.059%
$ 6.4m
James Wassil
Executive VP & COO5yrsUS$5.40m0.14%
$ 15.0m
Mikhail Eydelman
Senior VP2.7yrsUS$3.49m0.0086%
$ 922.1k
Ashish Khanna
Co-Founder11.9yrsno datano data
Jeff Fairman
Co-Founder & VP of Researchno datano datano data
Elvia Cowan
Senior VP of Finance & Principal Accounting Officer1.9yrsno data0.0093%
$ 1.0m
Janet Graesser
Senior Vice President of Corporate Communications & Investor Relationsno datano datano data
Whitney Jones
Chief People Officerless than a yearno datano data
Paul Sauer
Senior Vice President of Process Development & Manufacturing8.7yrsUS$2.35mno data
Harp Dhaliwal
Senior Vice President of Commercial Manufacturing & Supply Chain3.1yrsUS$1.84mno data
Sam Iki
Senior Vice President of Project Managementno datano datano data

4.6yrs

Average Tenure

55yo

Average Age

Experienced Management: PCVX's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder11.1yrsUS$12.14m0.52%
$ 55.7m
Annie Drapeau
Independent Director3.3yrsUS$704.22k0.0045%
$ 486.4k
K. Hirth
Independent Director8.3yrsUS$696.72k0.010%
$ 1.1m
Heath Lukatch
Independent Director6.6yrsUS$691.72k0.0045%
$ 486.4k
Halley Gilbert
Independent Director4.7yrsUS$704.22k0.0045%
$ 486.4k
Emmanuel Walter
Member of Scientific Advisory Boardno datano datano data
Carlos Paya
Independent Chairman of the Board3.2yrsUS$724.22k0.0045%
$ 486.4k
Anthony Ford-Hutchinson
Member of Scientific Advisory Boardno datano datano data
Jeffrey Almond
Member of Scientific Advisory Board7.9yrsno datano data
Teri Loxam
Independent Director3.3yrsUS$704.22k0.0045%
$ 486.4k
Emmanuel Hanon
Member of Scientific Advisory Boardno datano datano data
William Hausdorff
Member of Scientific Advisory Boardno datano datano data

5.6yrs

Average Tenure

57yo

Average Age

Experienced Board: PCVX's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vaxcyte, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Thomas ShraderBTIG
Louise ChenCantor Fitzgerald & Co.